RESI London 2024: A Global Gathering of Life Science Investors 

By Faith Patenaude, Investor Research Analyst, LSN

Faith

The upcoming Redefining Early Stage Investments (RESI) Conference in London is shaping up to be a remarkable event for life science innovators worldwide. The conference will be taking place in-person on December 4 at 11 Cavendish Square, followed by virtual partnering on December 5-6. RESI London 2024 is set to connect ambitious life science start-ups with a diverse array of early-stage investors and strategic partners from across the globe.

Featured RESI London Investors

RESI-London-CI

RESI’s reach goes well beyond the UK. While London-based investors like Delin Ventures, Boost Capital Partners, and Calculus Capital will be actively participating, RESI London 2024 will also welcome an extensive lineup of international firms, opening doors to far-reaching networks and growth opportunities.

European representation will be especially strong. In addition to local players, leading firms such as M Ventures from The Netherlands and CVX Ventures from Denmark will be present, providing crucial European connections for attending start-ups.

But the participation doesn’t stop at Europe. From the United States, esteemed investors like Optum Ventures and Lifespan Vision Ventures will take part in the event. Expanding beyond the Eastern Hemisphere, attendees can connect with firms such as Teijin Pharma from Japan, and Brandon Capital Partners from Australia, all of whom are eager to explore new partnerships with innovative life science start-ups.

RESI London 2024 offers an unparalleled chance to engage with a diverse and globally-minded group of investors. Interested in joining? Contact us at resi@lifesciencenation.com or click here to learn more.

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px

Innovating Together: Insights from BioJapan 2024 with Life Science Nation 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

A few weeks ago, Life Science Nation (LSN) headed to Yokohama to attend BioJapan 2024 from October 9-11, 2024. As one of the largest partnering conferences in Asia focused on the life sciences industry, this year’s event attracted over 18,000 attendees over the course of 3 days. For many years, BioJapan has served as a useful platform for LSN to expand its international network, including startups, investors/strategic partners, bioclusters, service providers, and more.

This year, LSN was invited by Life Science Incubation Council (LSIC) to join a seminar on “how life science startups in Japan can work together with global partners”. Founded in 2022, LSIC is a Japanese organization that has created a platform on which key players in the sector such as start-ups, VCs, pharmaceutical companies, medical device companies and government organizations can work together to develop innovative technology seeds, aiming towards commercialization of these technologies. LSN has signed an MOU with LSIC earlier this year to collaborate on initiatives to support the life sciences ecosystem in Japan.

Biojp

The seminar took place on the last day of BioJapan, Friday, October 11, and featured the following panelists: Claire Jeong (Life Science Nation), Hélène Moore (BIOQuébec), Angela Kukula (MedCity), and Toru Seo (NewSight Tech Angels). The seminar presented an opportunity for each panelist to shed more light into their activities and their respective ecosystems, and to provide guidance on how Japanese companies can establish better relationships with international partners for expanding their business on an international scale.

Biojp2

Shigehiro Asano (National Cerebral and Cardiovascular Center, Osaka), Claire Jeong (VP of Investor Research, Asia BD), Toru Seo (NewSight Tech Angels), Nao Yoshizawa (Life Science Incubation Council), Hélène Moore (BIOQuébec), Angela Kukula (MedCity), Tsuneaki Sakata (Osaka University / Biocommunity Kansai BiocK)

It was a great honor for LSN to share the panel with key industry experts and engage with more connections in Japan. LSN looks forward to continue providing a platform for life science and healthcare startups to connect with investors and strategic partners. Whether you are a startup seeking to identify more international investors and partners, or an investor seeking more international dealflow, please contact RESI@lifesciencenation.com if you are interested in learning more about how LSN can be helpful.

As with previous years, this year’s BioJapan was a very productive and well-executed event, and we look forward to returning next year!

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px

Hot Investor Profile: Corporate Venture Fund Invests in Early-Stage First-In-Class Therapeutics and Innovative Platform Technologies, Focusing on Companies in US and Europe

A strategic corporate venture capital fund of a pharmaceutical company seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities with a focus on US and Europe. 
 
The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the parent company’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications. 

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment. 
 
The firm is looking for teams with strong sector expertise. With the support of the firm’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm Seeks to Fund Innovative Therapeutics, Devices, and Diagnostics in Ophthalmology Across North America and Europe

A VC firm is expressly focused on funding ophthalmic innovation. The firm invests in therapeutics, devices, and diagnostics that improve and preserve vision. The firm looks to identify and bring forward early stage investments with our deep knowledge of the space. The firm is currently allocating $100k-$750k+ utilizing convertible notes and equity in early stage companies (seed to Series B). The firm will both lead and co-invest as part of a syndicate. The firm is currently seeking new opportunities based in North America and Europe. 
 
The firm specializes in early-stage investments in innovative ophthalmic diagnostic and treatment solutions. The firm seeks to invest in a broad range of technologies applicable to ophthalmology, including small molecule and biologic therapeutics, low and high-risk medical devices, diagnostics, drug delivery, and software solutions. The firm would also consider generic drugs but with less interest. The firm considers companies at all stages, but prefers early stage projects with some clinical or other supporting data where it can add meaningful expertise outside of financial capital. 
 
The firm seeks management teams formed by experienced entrepreneurs with track records of success and scientists with domain expertise in their field. The firm opportunistically seeks board seats on a deal-by-deal basis particularly in situations where they can add meaningful value. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: USA-Based VC Firm Seeks to Invest in Seed to Series B Life Science Companies, With a Focus on Therapeutics and Medical Devices 

A private venture capital firm based in the US focuses on early-stage life science and healthcare opportunities that can create a meaningful impact in the industry. The firm focuses on investments in Seed to Series B stages, with initial checks typically ranging from $250k to $1.5M and potential follow-on investments. The firm prefers co-investing and usually collaborates with syndicates for its investments, rather than leading investments. However, the firm is open to speaking with companies that do not have a lead investor in place. The firm only invests within the US. 
 
The firm is primarily focused on therapeutics and medical devices and will also consider diagnostics and lab equipment. However, the firm does not invest in software or digital health. The firm is more opportunistic in subsectors and indications, remaining open to different modalities and disease areas. Within the therapeutics sector, the firm has invested in small molecule and tRNA companies, and is open to considering rare diseases. Regarding the phase of development for therapeutics, The firm considers opportunities ranging from pre-clinical to phase II. For medical devices, the firm prefers to see certain validation, particularly first-in-human data, or animal data depending on the market. The firm is open to considering all classes of medical devices. 
 
The firm does not have specific requirements on companies’ founding or management teams. The firm is open to talking to both serial and first-time entrepreneurs. As an active investor, the firm is open to considering board or observer seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm Invests in USA-Based Seed-Stage Companies in the Fields of Digital Health and AI-Enabled Healthcare Technologies

A venture capital firm invests solely in AI-enabled software companies, focusing on cybersecurity, healthcare, vertical applications, enterprise infrastructure, biocomputation, and space and robotics. Typical check sizes are around USD $500k for U.S. companies seeking Seed rounds. Since 2010, the firm has invested in over 50 companies. 
 
In terms of healthcare, the firm invests in clinical digital health companies. The firm is not exclusive to digital health but sees AI as a key enabler. The firm would like to see companies with at least minimal revenue. 

The firm would like to see at least 2 members on the founding team that have complimentary skills: a member with healthcare experience and a technical lead with AI and software experience. The firm may take an observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

How to Succeed in Company Presentations/Pitches at Partnering Conferences: The Drive to Win, and What It Takes

Interview with Dennis Ford, Founder & CEO of Life Science Nation (LSN) By Claire Jeong, CCO, VP of Investor Research, Asia BD, LSN

DF-News-09142022Dennis Ford Claire-newClaire Jeong

In the high-stakes world of fundraising, competition is fierce, and success demands more than just a good idea—it requires strategy, persistence, and grit. At Life Science Nation (LSN), participant feedback helps us fine-tune our events to serve their needs better. Recently, concerns were raised about the fairness of the Innovator’s Pitch Challenge (IPC) at RESI Boston. In this forum, companies pitch to a panel of investor judges and audience, with some alleging that participants may have “gamed the system.” These observations point to a larger conversation about business dynamics—where determination often trumps traditional notions of fairness. In this candid interview, LSN’s CEO, Dennis Ford, explores the fine line between integrity, innovation, and the entrepreneurial hustle that drives results in a competitive environment.

Claire Jeong (CJ): What differentiates CEOs who succeed in fundraising from those who struggle, particularly in the context of RESI and the Innovator’s Pitch Challenge?
Dennis Ford (DF): The RESI IPC is a microcosm of the real-world fundraising landscape. Some CEOs adopt a proactive approach, while others wait for investors or licensing partners to approach them. The passive ones tend to wait for things to happen to them, while the proactive CEOs are out there making things happen. Just like in the real world, the ones who seize every opportunity are the ones who tend to succeed.

CJ: What mindset shift do you believe is critical for startup CEOs transitioning from academia to a competitive fundraising environment?
DF: Many startup CEOs, particularly those coming from academia, think that paying an entry fee, being selected to pitch, and setting up a poster is enough. They expect investors to naturally flock to them. However, that’s only a minimal effort. To truly excel at a partnering event like RESI, you need to actively seek out opportunities—engage with everyone who walks by, identify investors, and make sure they know who you are. This transition mirrors the shift from academia to the business world, where you’re no longer a scientist—you’re a salesperson, marketer, and business developer.

CJ: How important is balancing compelling science with a determined business development strategy in the fundraising process?
DF: Striking the right balance is essential. In fact, we’ve seen some of the more aggressive participants in the IPC go as far as asking people for their RESI dollars, getting colleagues to donate theirs, and working the system to gain attention. This is the point of the IPC – getting CEOs to put themselves out there and speak to as many attendees as possible. It gives companies many opportunities to practice their pitch, network, and push CEOs to tell as many people as possible their story. While it might not seem “fair” to some, this aggressive approach mirrors the cutthroat nature of fundraising. CEOs need to understand that they’re no longer just researchers—they’re operating in a startup environment where they need to fight for every dollar, every collaboration, and every opportunity.

CJ: Can you share examples of how startup CEOs who took a more aggressive approach achieved success at RESI or in their broader fundraising efforts?
DF: The CEOs who reframe their mindset and adopt a more aggressive approach are often the ones who succeed. The combination of preparation, hustle, and compelling science gives them a real chance. If a CEO lacks either preparation or hustle, the likelihood of failure increases. That’s why the failure rate in life science startups is so high. The process of translating science into a viable product is hard, and having a team willing to fully commit is even harder. But when you have that combination, you’re much more likely to succeed.

CJ: What advice would you give to CEOs who are hesitant to take an aggressive approach when engaging with investors at events like RESI?
DF: The hesitation is understandable, but this isn’t an environment where waiting around will get you anywhere. If you want to succeed, you have to go after it relentlessly. Yes, the market can be frustrating, and investors can be difficult, but those who adapt and push beyond their comfort zones are the ones who will secure funding. CEOs should view it as a way to practice their elevator pitch and refine their story – speaking to 100 people in the quest to gain RESI cash will help companies refine their pitch a lot more than if they stick to only speaking to people with whom they have scheduled meetings.

CJ: How does participation in the RESI IPC competition reflect the real-world challenges life science startups face in fundraising?
DF: The RESI IPC mirrors the fundraising marketplace perfectly. We’ve run about 50 of these competitions over the last twelve years, and the pattern is always the same—some participants hustle hard, others take a more passive approach, and many learn and improve as they go. What’s interesting is that the startups who win IPC prizes—based on votes from both RESI dollars and judges—tend to be the ones who also succeed outside of the competition. They’ve become guerrilla marketers and street fighters, combining that tenacity with a solid product and milestones. Success in the technology and innovation space has always required that mix of drive and substance, and it always will.

The RESI Innovator’s Pitch Challenge is not just a competition; it’s a testing ground for the broader fundraising landscape. It rewards those who balance science with the hustle, pushing past the perceived limits of fairness to carve out their path in the startup ecosystem. The lesson? If you want to succeed, you must be willing to fight for it—aggressively, intelligently, and relentlessly.

Apply Pitch at RESI London Apply Pitch at RESI JPM

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px